Tip 2 Diyabetli Hastalarda Diyet, Sülfonilüre Grubu Oral Antidiyabetik İlaçlar Ve İnsülin Tedavisinin Kan Şekeri Üzerindeki Etkileri+
Yükleniyor...
Dosyalar
Tarih
1999
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turgut Özal Tıp Merkezi Dergisi
Erişim Hakkı
Attribution 3.0 United States
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Özet
Bu randomize prospektif çalışmada, tip 2 diyabetli hastalarda diyet, giiklazid, gliklazid ile akarboz ve insülin tedavilerinin kan şekeri üzerine etkileri araştırıldı. Açlık kan şekeri 140 ile 270 mg/dL arasında değişen ve ortalama yaşlan 50.83± 6.88 (36-66) yıl olan 30 erkek (12 obez ve 18 nonobez) ve 34 kadın (20 obez ve 14 nonobez) toplam 64 hasta çalışmaya alındı. Hastalar randomize edilmeden önce iki gruba ayrıldı (obez ve nonobez) ve her iki grup kendi içinde diyet, gliklazid, gliklazid ile akarboz ve insülin tedavilerinden oluşan 4 alt gruba ayrıldı. Hastalar 14. ve 28. haftalarda tekrar değerlendirildi. Tedavi öncesinde, ortalama (±SD) açlık kan şekeri 203.43 (27.05) mg/dl, HbAc %8.38 (0.71), vücut ağırlığı 76.78 (7.25) kg, açlık plazma insülini 33.85 (7.49) g/ml ve C-peptid 4.08 (0.76) ng/ml idi. Yedi aylık tedavi sonrasında, ortalama (±SD) açlık kan şekerinde 23.14 (10.62) mg/dl ve HbAc 'de %0.59 (0.08) düşme görüldü. Açlık plazma insülinde 1.97 (0,44) g/ml'lik, C- peptid seviyesinde 2.03 (0.07) ng/ml'lik ve vücut ağırlığında 1.69 (0.05) kglk artış saptandı. Sonuç olarak, hastalarda gliklazid, gliklazid ile akarboz ve insülin tedavilerin, sadece diyet tedavisinden daha etkili olduğu görüldü. Bununla bimkte, tedavi gruplar arasında metabolik durumu düzeltme açısından önemli bir fark saptanmadı.
In this randomized prospective study, we investigated the effects of diet, gliclazide, gliclazide and acarbose and insulin on blood glucose levels of Type 2 diabetic patients. Sixty-four patients, 30 males (12 obese and 18 non-obese) and 34 females (20 obese and 14 non-obese), aged 50.83±6.88 years (range 36-66) with a fasting blood glucose level of 140 to 270 mg/dL zere included. Patients were divided into two groups (obese and nonobese) before randomization and both groups were divided into four subgroups consisting of diet, gliclazide, gliclazide and acarbose and insulin. Patients zere re-evaluated at 14 and 28 weeks. Prior to study, mean (± SD) fasting blood glucose level was 203.43 (27.05) mg/dl, HbA1c was 8.38°% (0.71), body weıght was 76.78 (7.25) kg, fasting plasma insulin was 33.85 (7.49) g/ml, and C- peptide level was 4.08 (0.76) ng/ml. After seven months of treatment, mean (± SD) decrease in fasting blood glucose level was 23.14 (10.62) mg/dl and 0.59°% (0.08) in HbA1c. There was an increase of 1.69 (0.05) kg in body weight, 1.97 (0,44) g/ml in fasting plasma insulin, and 4.08 (0.76) ng/ml in C-peptide levels. In conclusi on, we observed that gliclazide, gliclazide and acarbose, and insulin treatments were more effective than diet alone. However, no signi ficant difference was observed between treatment groups in terms of improved metabolic state.
In this randomized prospective study, we investigated the effects of diet, gliclazide, gliclazide and acarbose and insulin on blood glucose levels of Type 2 diabetic patients. Sixty-four patients, 30 males (12 obese and 18 non-obese) and 34 females (20 obese and 14 non-obese), aged 50.83±6.88 years (range 36-66) with a fasting blood glucose level of 140 to 270 mg/dL zere included. Patients were divided into two groups (obese and nonobese) before randomization and both groups were divided into four subgroups consisting of diet, gliclazide, gliclazide and acarbose and insulin. Patients zere re-evaluated at 14 and 28 weeks. Prior to study, mean (± SD) fasting blood glucose level was 203.43 (27.05) mg/dl, HbA1c was 8.38°% (0.71), body weıght was 76.78 (7.25) kg, fasting plasma insulin was 33.85 (7.49) g/ml, and C- peptide level was 4.08 (0.76) ng/ml. After seven months of treatment, mean (± SD) decrease in fasting blood glucose level was 23.14 (10.62) mg/dl and 0.59°% (0.08) in HbA1c. There was an increase of 1.69 (0.05) kg in body weight, 1.97 (0,44) g/ml in fasting plasma insulin, and 4.08 (0.76) ng/ml in C-peptide levels. In conclusi on, we observed that gliclazide, gliclazide and acarbose, and insulin treatments were more effective than diet alone. However, no signi ficant difference was observed between treatment groups in terms of improved metabolic state.
Açıklama
Turgut Özal Tıp Merkezi Dergisi.6 (2) :1999. İnönü Üniversitesi, Malatya.
Anahtar Kelimeler
Tip 2 diyabet, diyet, gliklazid, akarboz, insülin, Type 2 diabetes, diet, gliclazide, acarbose, insulin
Kaynak
İnönü Üniversitesi Turgut Özal Tıp Merkezi Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
6
Sayı
2
Künye
Çağın, Furkan ,Şavlı, Haluk ,Serbest, Servet ,Sevinç, Alper ,Büyükberber, Süleyman ,Turgut Özal Tıp Merkezi Dergisi.6 (2) :1999. İnönü Üniversitesi, Malatya.
